Founded in July 2019 by Prof. Dr. Jens Schwamborn and Dr. Javier Jarazo, the biotech company OrganoTherapeutics S.a.r.l. (OT) makes use of a proprietary human-specific 3D in vitro model, the so-called midbrain organoids, for the discovery and development of effective drug candidates, which target neurodegeneration in Parkinson`s disease (PD) patients. The business model of OT is to use patient specific midbrain organoids for the discovery and development of own drugs. At a later stage of development, revenues will be generated by out-licensing these drug candidates.
Content by this speaker
Further Activities to have a look at